Revolutionising Thrombosis Treatment in ACS, SSP and AF: Bridging the Gaps With Next Generation Anticoagulation Strategies
-
9m 54s
-
8m 27s
-
12m 51s
-
4m 7s
Join Prof Carolyn Lam as she introduces the session, exploring thrombosis management in acute coronary syndrome, secondary stroke prevention and atrial fibrillation.
Presented at the European Society of Cardiology (ESC) Congress 2025, Prof Carolyn Lam (Singapore, UK), Prof Davide Capodanno (Catania, IT), Dr Sneha Shah Jain (Stanford, US) and Prof Jeffrey Weitz (Hamilton, CA) examine the prevalence and challenges of stroke prevention in atrial fibrillation (AF) and after acute coronary syndrome (ACS). The faculty review current treatment guidelines, explore factor XI and innovations in antithrombotics and discuss how clinical trial evidence may shape practice.
Through expert conversation and a compelling real-world case, they highlight the complexities of treatment and why delivering guideline-directed medical therapy remains such a challenge in this high-risk group.
Note: The live version of this satellite symposium was accredited. For the on-demand CME-accredited course, please click the link below:
Learning Objectives
- Discuss the unmet needs in thrombosis management, MACE burden after ACS, stroke in AF and secondary stroke prevalence and consequences
- Evaluate the current standard of care for the treatment of ACS, SSP and AF and its limitations
- Review guidelines and critique current prescribing practices and the implications of inadequate treatment
- Explain the different strategies for targeting FXI and how FXI inhibition mechanisms differentiate from traditional anticoagulation therapies
- Identify emerging anticoagulant strategies and describe the efficacy and safety data from Phase 2 FXI inhibitor clinical trials as well as ongoing Phase 3 trials and potential place in therapy for ACS, AF and SSP
- Apply evidence-based anticoagulation strategies by optimising treatment decisions and addressing patient-specific risk factors
Target Audience
- Cardiologists
- Interventional Cardiologists
- Electrophysiologists
- Cardiac Surgeons
- Primary Care Practitioners
- HCPs involved in the care of ACS, AF, and SSP
More from this programme
Part 1
Welcome
Part 2
Stroke Prevention in AF and MACE after ACS: Prevalence and Challenges
Prof Davide Capodanno explores the unmet needs in thrombosis management, focusing on stroke burden in AF and recurrent events after ACS.
Part 3
Current Treatments in AF and ACS, Safety and Guidelines
Dr Sneha Shah Jain reviews the current standard of care, key guideline recommendations and the limitations of prescribing practices in AF and ACS.
Part 4
Targeting Factor XI: Innovations in Anticoagulation
Prof Jeffrey Weitz examines strategies for FXI inhibition, explains how these differ from traditional anticoagulants and reviews emerging safety and efficacy data.
Part 5
Shaping Clinical Practice and Clinical Trials
Prof Carolyn Lam highlights insights from clinical trial evidence and discusses how evolving anticoagulant strategies may influence future clinical practice.
Part 6
Audience Q&A and Closing Remarks
The faculty respond to audience questions and reinforce the key take-home messages for evidence-based treatment in high-risk patient groups.
| 1 session | |
| Audience Q&A and Closing Remarks | Watch now |
Faculty Biographies
Carolyn Lam
Professor and Senior Consultant Cardiologist
Prof Carolyn Lam is a Senior Consultant Cardiologist and Director of Women’s Heart Health at the National Heart Centre Singapore, where she pioneered the country’s first Women’s Heart Clinic. Internationally recognised for her expertise in heart failure with preserved ejection fraction (HFpEF), Prof Lam has played a key role in landmark clinical trials including PARAGON-HF, EMPEROR-Preserved, DELIVER and FINEARTS-HF.
Her work helped establish the first FDA-approved treatment for HFpEF and the first trial to demonstrate robust clinical benefit in this patient population. A prolific researcher, Prof Lam has authored over 700 peer-reviewed publications in top journals such as New England Journal of Medicine, Lancet, JAMA, Circulation and
Davide Capodanno
Professor of Cardiology and Interventional Cardiologist
Prof Davide Capodanno is Professor of Cardiology at the University of Catania and Interventional Cardiologist at the Azienda Ospedaliero Universitaria “Policlinico G. Rodolico-S. Marco”, Catania, IT. He is internationally recognised for his expertise in interventional cardiology, thrombosis and cardiovascular clinical research.
With over 500 peer-reviewed publications, five interventional cardiology textbooks and 17 textbook chapters, Prof Capodanno is a prolific author and respected speaker, having delivered more than 200 invited lectures at global cardiology congresses. He is Co-Director of the PCR Clinical Research Course and Associate Director of TCT, two leading platforms for education in cardiovascular interventions.
Prof Capodanno is Editor-in-Chief of EuroIntervention, Associate Editor of the
Sneha Jain
Clinical Assistant Professor of Medicine and Director of the GUIDE-AI Lab
Dr Sneha Shah Jain is Clinical Assistant Professor of Medicine and Director of the GUIDE-AI Lab at Stanford Health Care, US.
She specialises in cardiovascular medicine and preventive cardiology. Her academic background includes an Economics degree with distinction from Duke University, a medical degree from Johns Hopkins School of Medicine and an MBA from Harvard Business School. She completed internal medicine residency at Columbia/NewYork-Presbyterian and cardiovascular fellowship at Stanford University.
Dr Jain leads research in artificial intelligence (AI) for cardiovascular care, focusing on safe, evidence-based implementation to enhance patient outcomes. She collaborates with the Data Science Team at Stanford Healthcare and the Stanford Center for Clinical Research to deploy and prospectively evaluate clinical AI tools.
She holds leadership roles in national cardiovascular innovation, serving on the American College of Cardiology Healthcare Innovation…
Jeffrey Weitz
Professor of Medicine and Biochemistry and Biomedical Sciences & Executive Director
Prof Jeffrey I Weitz is Professor of Medicine and Biochemistry and Biomedical Sciences at McMaster University and Executive Director of the Thrombosis & Atherosclerosis Research Institute (TaARI), Hamilton, CA.
He is Past President of the International Society on Thrombosis and Haemostasis and board certified in internal medicine, haematology and medical oncology. Dr Weitz specialises in the care of patients with thrombotic disorders.
His internationally recognised research spans the biochemistry of blood coagulation and fibrinolysis, preclinical thrombosis models and clinical trials of antithrombotic therapies. He has authored over 650 publications across journals such as Blood, Circulation, Lancet, New England Journal of Medicine, Journal of Clinical Investigation and Annals of Internal Medicine, as well as 76 book chapters.
Prof Weitz is an Officer of the Order of Canada and a Fellow of the…